Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term ...

Citi lowered the firm’s price target on Regeneron (REGN) to $750 from $795 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and ...

On Wednesday, RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm ...

BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares. The firm is updating its model following “disappointing ...

On Wednesday, Truist Securities revised its price target for Regeneron Pharmaceuticals stock, traded on (NASDAQ: REGN), lowering it to $975 from the previous target of $1,004.

On Tuesday, Morgan Stanley (NYSE:MS) adjusted its outlook on Regeneron (NASDAQ:REGN) Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00. Despite the decrease, the firm ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,215 from $1,260 but keeps an Outperform rating on the shares. The extent of the stock’s downside following Q3 earnings are ...

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Outperform rating on the shares. The company reported Q3 revenue in ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday,Benzinga ...

Regeneron Pharmaceuticals Inc : * Jefferies raises Regeneron Pharmaceuticals price target to $163 from $127; rating buy For a summary of rating and price target changes on U.S. companies: Reuters ...

On Wednesday, Wells Fargo (NYSE:WFC) adjusted its financial outlook for Regeneron (NASDAQ:REGN) Pharmaceuticals, reducing the price target on the company's shares to $1,050 from the previous $1,200.